Search Results - "ESKENS, Ferry A. L. M"

The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets by van Riet, Job, van de Werken, Harmen J. G., Cuppen, Edwin, Eskens, Ferry A. L. M., Tesselaar, Margot, van Veenendaal, Linde M., Klümpen, Heinz-Josef, Dercksen, Marcus W., Valk, Gerlof D., Lolkema, Martijn P., Sleijfer, Stefan, Mostert, Bianca

“…Metastatic and locally-advanced neuroendocrine neoplasms (aNEN) form clinically and genetically heterogeneous malignancies, characterized by distinct prognoses…”
Get full text

Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial by Belkouz, Ali, de Vos-Geelen, Judith, Mathôt, Ron A. A., Eskens, Ferry A. L. M., van Gulik, Thomas M., van Oijen, Martijn G. H., Punt, Cornelis J. A., Wilmink, Johanna W., Klümpen, Heinz-Josef

“…Background No standard treatment is available for advanced biliary tract cancer (BTC) after first-line therapy with gemcitabine plus cisplatin (GEMCIS). The…”
Get full text

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study by Suker, Mustafa, Nuyttens, Joost J., Groot Koerkamp, Bas, Eskens, Ferry A. L. M., Eijck, Casper H. J.

“…Introduction One‐third of the patients with pancreatic cancer present with locally advanced unresectable pancreatic cancer (LAPC). Our aim was to determine…”
Get full text

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors by Marshall, John, Hwang, Jimmy, Eskens, Ferry A. L. M., Burger, Herman, Malik, Shakun, Uttenreuther-Fischer, Martina, Stopfer, Peter, Ould-Kaci, Mahmoud, Cohen, Roger B., Lewis, Nancy L

“…Summary Background A Phase I study to determine the maximum tolerated dose (MTD) and pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family…”
Get full text

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study by Vermunt, Marit A. C., Robbrecht, Debbie G. J., Devriese, Lot A., Janssen, Julie M., Thijssen, Bas, Keessen, Marianne, Eijk, Maarten, Kessels, Rob, Eskens, Ferry A. L. M., Beijnen, Jos H., Mehra, Niven, Bergman, Andries M.

“…Background ModraDoc006 is an oral formulation of docetaxel, which is co‐administered with the cytochrome P450 3A4 and P‐glycoprotein inhibitor ritonavir (r):…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors by ESKENS, Ferry A. L. M, RAMOS, Francisco J, TABERNERO, Josep, BURGER, Herman, O'BRIEN, James P, PIERA, Adelaida, DE JONGE, Maja J. A, MIZUI, Yoshiharu, WIEMER, Erik A. C, CARRERAS, Maria Josepa, BASELGA, José

“…To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8,…”
Get full text

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review by Eskens, Ferry A.L.M., Verweij, Jaap

“…Clinical experience with vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors is…”
Get full text

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma by Jones, Robert J., Hawkins, Robert E., Eatock, Martin M., Ferry, David R., Eskens, Ferry A. L. M., Wilke, HansJochen, Evans, T. R. Jeffry

“…Purpose Combination chemotherapy regimens can improve survival in patients with advanced gastric and oesophageal adenocarcinoma. Docosahexaenoic acid…”
Get full text

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform by Zeverijn, Laurien J, van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh, van Roy, Anke A M G Pisters, Timmers, Lonneke, Ly Tran, T H, de Boer, Jolanda E, de Wit, Gijsbrecht F, Geurts, Birgit S, Gelderblom, Hans, Verheul, Henk M W, Blijlevens, Nicole, Wymenga, A N Machteld, Eskens, Ferry A L M, Smit, Egbert F, Bloemendal, Haiko J, Voest, Emile E

“…In Europe, an EAP is often considered an open-label extension study aiming to provide access to a medicine and generate additional safety data, whereas the…”
Get full text

A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours by Robbrecht, Debbie G. J., Lopez, Juanita, Calvo, Emiliano, He, Xiaomin, Hiroshi, Hirai, Soni, Nital, Cook, Natalie, Dowlati, Afshin, Fasolo, Angelica, Moreno, Victor, Eskens, Ferry A. L. M., de Bono, Johann S.

“…Background This is a first-in-human study with TAS-119, an Aurora A kinase (AurA) inhibitor. Methods Patients with advanced, refractory, solid tumours were…”
Get full text

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors by ESKENS, Ferry A. L. M, DE JONGE, Maja J. A, VERWEIJ, Jaap, BHARGAVA, Pankaj, ISOE, Toshiyuki, COTREAU, Monette M, ESTEVES, Brooke, HAYASHI, Kunihiko, BURGER, Herman, THOMEER, Maarten, VAN DOORN, Leni

“…To assess the maximum tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective…”
Get full text

Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension by van Doorn, Leni, Visser, Wesley J., van Dorst, Daan C. H., Mirabito Colafella, Katrina M., Koolen, Stijn L. W., de Mik, Anneke van Egmond, Garrelds, Ingrid M., Bovée, Dominique M., de Hoop, Esther Oomen, Bins, Sander, Eskens, Ferry A. L. M., Hoorn, Ewout J., Jan Danser, A. H., Mathijssen, Ron H. J., Versmissen, Jorie

“…Background Vascular endothelial growth factor inhibitors (VEGFIs) are effective anticancer agents which often induce hypertension. VEGFI-induced hypertension…”
Get full text

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer by van Geel, Robin M. J. M., van Brummelen, Emilie M. J., Eskens, Ferry A. L. M., Huijberts, Sanne C. F. A., de Vos, Filip Y. F. L., Lolkema, Martijn P. J. K., Devriese, Lot A., Opdam, Frans L., Marchetti, Serena, Steeghs, Neeltje, Monkhorst, Kim, Thijssen, Bas, Rosing, Hilde, Huitema, Alwin D. R., Beijnen, Jos H., Bernards, René, Schellens, Jan H. M.

“…Background Mutations in KRAS result in a constitutively activated MAPK pathway. In KRAS -mutant tumours existing treatment options, e.g. MEK inhibition, have…”
Get full text

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib by Labeur, Tim A., Berhane, Sarah, Edeline, Julien, Blanc, Jean‐Frederic, Bettinger, Dominik, Meyer, Tim, Van Vugt, Jeroen L. A., Ten Cate, David W. G., De Man, Robert A., Eskens, Ferry A. L. M., Cucchetti, Alessandro, Bonnett, Laura J., Van Delden, Otto M., Klümpen, Heinz‐Josef, Takkenberg, R. Bart, Johnson, Philip J.

“…Background The ‘Prediction Of Survival in Advanced Sorafenib‐treated HCC’ (PROSASH) model addressed the heterogeneous survival of patients with hepatocellular…”
Get full text

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors by SOEPENBERG, Otto, DE JONGE, Maja J. A, SPARREBOOM, Alex, DE BRUIN, Peter, ESKENS, Ferry A. L. M, DE HEUS, Gerda, WANDERS, Jantien, CHEVERTON, Peter, DUCHARME, Murray P, VERWEIJ, Jaap

“…Purpose: To assess the maximum-tolerated dose, toxicity, and pharmacokinetics of DE-310, a macromolecular prodrug of the topoisomerase I inhibitor exatecan…”
Get full text

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit? by Eskens, Ferry ALM, Sleijfer, Stefan

“…Abstract Bevacizumab is approved for the treatment of colorectal cancer, breast cancer, non-small cell lung cancer and renal cell cancer. Before embracing this…”
Get full text

The yield of chest computed tomography in patients with locally advanced pancreatic cancer by Suker, Mustafa, Groot Koerkamp, Bas, Nuyttens, Joost J., Dwarkasing, Roy S., Homs, Marjolein Y. V., Eskens, Ferry A. L. M., Eijck, Casper H. J.

“…Objective To evaluate the incidence of pulmonary metastases on chest computed tomography (CT) in patients with locally advanced pancreatic cancer (LAPC)…”
Get full text

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors by Hamid, Omid, Chiappori, Alberto A, Thompson, John A, Doi, Toshihiko, Hu-Lieskovan, Siwen, Eskens, Ferry A L M, Ros, Willeke, Diab, Adi, Spano, Jean-Philippe, Rizvi, Naiyer A, Wasser, Jeffrey S, Angevin, Eric, Ott, Patrick A, Forgie, Alison, Yang, Wenjing, Guo, Cen, Chou, Jeffrey, El-Khoueiry, Anthony B

“…BackgroundIvuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This…”
Get full text

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma by Dijkstra, Krijn K, van den Berg, José G, Weeber, Fleur, van de Haar, Joris, Velds, Arno, Kaing, Sovann, Peters, Dennis D G C, Eskens, Ferry A L M, de Groot, Derk-Jan A, Tesselaar, Margot E T, Voest, Emile E

“…Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a poorly understood disease with limited treatment options. A better understanding of this disease…”
Get full text

Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634 by Atrafi, Florence, van Eerden, Ruben A. G., Koolen, Stijn L. W., de Bruijn, Peter, Rijcken, Cristianne J. F., Hanssen, Rob, Eskens, Ferry A. L. M., Lolkema, Martijn P., Oomen-de Hoop, Esther, Damman, Jeffrey, Mathijssen, Ron H. J.

“…Docetaxel entrapped nanoparticle CPC634 is associated with dose-related skin toxicity that resembles conventional docetaxel (Cd)-related skin toxicity. This…”
Get full text